Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
19.05
+0.74 (4.04%)
Feb 26, 2026, 3:12 PM EST - Market open
Caris Life Sciences Stock Forecast
Stock Price Forecast
The 8 analysts that cover Caris Life Sciences stock have a consensus rating of "Strong Buy" and an average price target of $33.63, which forecasts a 76.54% increase in the stock price over the next year. The lowest target is $26 and the highest is $42.
Price Target: $33.63 (+76.54%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Caris Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Initiates $26 | Buy | Initiates | $26 | +36.48% | Feb 17, 2026 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $28 → $30 | Hold | Maintains | $28 → $30 | +57.48% | Dec 22, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Initiates $28 | Hold | Initiates | $28 | +46.98% | Dec 2, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $32 → $36 | Strong Buy | Maintains | $32 → $36 | +88.98% | Aug 13, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $33 → $40 | Buy | Maintains | $33 → $40 | +109.97% | Aug 13, 2025 |
Financial Forecast
Revenue This Year
758.10M
from 412.26M
Increased by 83.89%
Revenue Next Year
998.25M
from 758.10M
Increased by 31.68%
EPS This Year
-2.19
from -10.66
EPS Next Year
0.19
from -2.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 840.1M | 1.1B | ||||
| Avg | 758.1M | 998.3M | ||||
| Low | 708.5M | 938.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 103.8% | 41.1% | ||||
| Avg | 83.9% | 31.7% | ||||
| Low | 71.9% | 23.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.11 | 0.48 | ||
| Avg | -2.19 | 0.19 | ||
| Low | -8.22 | -0.14 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.